All In Biotech

Drug Trial Radar · NCT07630155

Office-Based Ureteroscopy Utilizing a Single Use Digital, Flexible Ureteroscope for Upper Tract Urothelial Carcinoma

A Prospective Clinical Assessment of Office-Based Ureteroscopy for Upper Tract Urothelial Carcinoma Utilizing a 6.3 French Single Use Digital Flexible Ureteroscope

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Oct 26, 2026

Primary completion

Oct 2027

Study completion Oct 2027

Sponsor

Lead sponsor
University of Michigan Rogel Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shenzhen HugeMed Medical Technical Development
First posted
Jun 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial tests how well office based ureteroscopy utilizing a single use digital, flexible ureteroscope works for the assessment of upper tract urothelial carcinoma. Ureteroscopy is a procedure in which a thin camera called a ureteroscope is used to assess patients with a known or suspected diagnosis of upper tract urothelial carcinoma. Ureteroscopy is traditionally performed in an operating room under general anesthesia. In this study, patients undergo ureteroscopy in the doctor's office using an ultra-thin ureteroscope, which is the narrowest instrument of its kind. Because of its small size, researchers believe this procedure can be completed in the office with minimal discomfort and high patient satisfaction, which may eliminate the risks of general anesthesia and reduce delays to diagnosis. Office based ureteroscopy utilizing a single use digital, flexible ureteroscope may be effective for the assessment of upper tract urothelial carcinoma.

Conditions

  • Renal Pelvis and Ureter Urothelial Carcinoma

Interventions

  • Analgesic AgentDrug

    Given PO

  • Electronic Health Record ReviewOther

    Ancillary studies

  • Lidocaine TopicalDrug

    Given intraurethrally

  • Medical Device Usage and EvaluationDevice

    Undergo ureteroscopy using 6.3 Fr single use digital ureteroscope

  • Survey AdministrationOther

    Ancillary studies

  • UreteroscopyProcedure

    Undergo ureteroscopy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Success rateTime frame: On day of procedure

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.